SEC Form 4 · accession 0001209191-15-034321
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harry J Leonhardt
Officer — SVP, GC and CCO
Period of report
Apr 13, 2015
Accepted (ET)
Apr 15, 2015 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $15.63 | Apr 13, 2015 | A | 225,000 | A | Apr 13, 2016 | Apr 13, 2025 | Common Stock | 225,000 | 225,000 | D |
| Restricted Stock UnitsF2 | $0.00 | Apr 13, 2015 | A | 27,500 | A | Apr 13, 2016 | Apr 13, 2025 | Common Stock | 27,500 | 27,500 | D |
Explanation of responses
- F1This option vests one-fourth on such date and 1/48 monthly thereafter.
- F2This award vests one-fourth on such date and one-fourth on each anniversary thereafter.